Keytruda 100 MG/4 ML vial 4ML
Ended Awarded Last action
- Contract number
- SPE2DR26FMED3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $26,237
Award facts
- Contract value 100% obligated
- $26,236.77 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $26,236.77 by the Defense Logistics Agency on January 2, 2026, for the supply of Keytruda 100 mg/4 mL vials. The award carries an ultimate completion date of January 26, 2026, and was issued without a set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which was awarded on November 13, 2025.
The PPV-G GEN V program represents a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors to supply comprehensive pharmaceutical products and medical consumables to support Department of Defense healthcare operations globally. DMS Pharmaceutical Group's IDC carries a ceiling value of $499,999,999 with a performance period extending through December 31, 2036, structured as a 30-month base period with three 30-month option periods. The company's demonstrated expertise in distributing oncology treatments, biologics, vaccines, and specialty pharmaceuticals positions it as a critical supplier within the federal military medical supply chain, with this delivery order representing one of numerous firm fixed-price orders for Keytruda and other specialized pharmaceutical products supporting DoD healthcare requirements.
Quick answers
Who was awarded contract SPE2DR26FMED3?
SPE2DR26FMED3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 2, 2026.
How much is contract SPE2DR26FMED3 worth?
The government has obligated $26,237 on SPE2DR26FMED3.
Is contract SPE2DR26FMED3 an order under another contract?
Yes. SPE2DR26FMED3 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMED3 competed?
The extent of competition for SPE2DR26FMED3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award